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Abstract
Background—Proton magnetic resonance spectroscopy (1H-MRS) studies on healthy aging
have reported inconsistent findings and have not systematically taken into account the possible
modulatory effect of APOE genotype. We aimed to quantify brain metabolite changes in healthy
subjects in relation to age and the presence of the APOE E4 genetic risk factor for Alzheimer's
disease. Additionally, we examined these measures in relation to cognition.
Methods—We studied a cohort of 112 normal adults between 50 and 86 years old who were
genotyped for APOE genetic polymorphism. Measurements of 1H-MRS metabolites were obtained
in the posterior cingulate and precuneus region. Measures of general cognitive functioning,
memory, executive function, semantic fluency, and speed of processing were also obtained.
Results—General linear model analysis demonstrated that older APOE E4 carriers had
significantly higher choline/creatine and myoinositol/creatine ratios than APOE E3 homozygotes.
Structural equation modeling resulted in a model with an excellent goodness of fit and in which
the APOE × age interaction and APOE status each had a significant effect on 1H-MRS metabolites
(choline/creatine and myo-inositol/creatine). Furthermore, the APOE × age variable modulation of
cognition was mediated by 1H-MRS metabolites.
Conclusions—In a healthy aging normal population, choline/creatine and myo-inositol/creatine
ratios were significantly increased in APOE E4 carriers, suggesting the presence of
neuroinflammatory processes and greater membrane turnover in older carriers. Structural equation
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modeling analysis confirmed these possible neurodegenerative markers and also indicated the
mediator role of these metabolites on cognitive performance among older APOE E4 carriers.
Keywords
Aging; APOE genotype; cognitive function; neurodegeneration; proton magnetic resonance
spectroscopy; structural equation modeling
Proton magnetic resonance spectroscopy (1H-MRS) has become a useful technique to
measure the concentration of brain metabolites in vivo. Numerous studies have
examined 1H-MRS metabolite ratios in patients with Alzheimer's disease (AD). There is
strong evidence that abnormalities in myo-inositol (mI)/creatine (Cr) and choline (Cho)/Cr
ratios in the posterior cingulate/precuneus region are present in AD and mild cognitive
impairment (MCI) (mean effect size [ES] of .91 in four studies and mean ES of .71 in three
studies, respectively) (1–4). N-acetylaspartate (NAA)/Cr ratios have been found to be
reduced in subjects with AD and MCI (mean ES of −.60 in four studies). (For more details,
see Table S1 in Supplement 1.) The precuneus and posterior cingulate region is affected
relatively early in AD, as reflected by reduced cortical thickness (5), amyloid deposition (6),
and functional imaging and metabolic alterations (7).
To the best of our knowledge, there has been only a single 1H-MRS study of the impact of
APOE genotype in otherwise healthy individuals at risk for AD by virtue of carrying the
APOE E4 allele, the strongest genetic risk factor for late-onset AD (8). In a sample that
included only a small number of E4 carriers (n = 8), APOE genotype did not have significant
effects on 1H-MRS metabolites or on general cognitive function and memory performance
(3).
Nevertheless, given APOE effects on multiple AD-related biomarkers, including
fluorodeoxyglucose-positron emission tomography (9), β-amyloid measures (10), and
medial temporal atrophy (11), we posited that APOE effects on 1H-MRS metabolites may be
observable in a larger sample of healthy individuals using advanced statistical approaches.
Thus, we tested the prediction that APOE E4 status would interact with age such that
differentially higher Cho/Cr and mI/Cr ratios and lower NAA/Cr ratios would be found in
older E4 subjects. Specifically, we wanted to examine APOE genotype × age interactions
because of the possibility that genotypic differences might become increasingly larger with
age due to diminished cognitive reserve, redundancy in neural systems, and/or compensatory
potential (12).
We also sought to determine relationships among APOE genotype, age, 1H-MRS
metabolites, and cognition by means of structural equation modeling, a pathway-based
statistical technique. We predicted that APOE genotype and/or its interaction with age would
impact cognition when mediated by 1H-MRS measures. The construction of the model
specified simultaneous causal paths among APOE genotype, age, and their interaction
through 1H-MRS metabolites to cognitive measures. In this way, we were able to determine
that APOE genotype directly or in interaction with age significantly modulated Cho/Cr and
mI/Cr ratios, and furthermore, from our structural equation model, that mI/Cr ratios
appeared to mediate the relationship between genotype and cognition.
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Methods and Materials
Participants
Participants (n = 112) were cognitively healthy subjects recruited at the Litwin-Zucker
Research Center for the Study of Alzheimer's Disease and Memory Related Disorders. All
potential participants underwent examination by a neurologist or a geriatric psychiatrist to
determine study eligibility. All subjects were between the ages of 50 and 86 years, had Mini-
Mental State Examination score ≥24, and did not meet Petersen's criteria for MCI (see
Supplement 1 for a detailed description of exclusionary criteria).
All procedures were approved by the North Shore-Long Island Jewish Health System
Institutional Review Board. All the subjects included in the study signed written informed
consent for participation.
Genotyping
Genotyping was conducted by Polymorphic DNA at two loci in APOE exon 4 by amplicon
sequencing methods to produce small polymerase chain reaction products that serve as
templates for bidirectional sequencing. There were 89 APOE E3 homozygotes and 23 E4
carriers (4 of whom were APOE E4 homozygotes). APOE E2 carriers were excluded
because of the low number of E2 carriers in our dataset and the putative neuroprotective
effects of the E2 allele, which could confound these analyses.
Proton Magnetic Resonance Spectroscopy
A mid-sagittal oblique 10.8 cm3 (2 × 2 × 2.7 cm) voxel was prescribed in the region of the
precuneus and posterior cingulate cortex (Figure S1 in Supplement 1). The 1H-MRS voxel
was placed midway between the parieto-occipital sulcus and the marginal branch of the
cingulate sulcus, with the long axis parallel to these sulci, covering the precuneus and
posterior cingulate region. Double spin-echo point resolved spectroscopy spectra were
acquired on a GE Twinspeed 3T magnetic resonance imaging scanner with HDx technology,
using an 8-channel phased array head coil (GE Healthcare, Milwaukee, Wisconsin), with
128 excitations acquired at repetition time = 1600 msec and echo time = 30 msec (see
Supplement 1 for a detailed description of the procedure).
We elected to measure metabolites in the precuneus/posterior cingulate region, because it is
known to demonstrate early changes in the default mode network (13), increases in
Pittsburgh Compound B binding (14), an abnormal mitochondrial transcriptional profile
(15), positron emission tomography glucose hypometabolism in younger E4 carriers (9), and
AD type histopathology (16) at early stages of the disease. These features are considered
important biomarkers in the transition from normal aging to MCI and MCI to AD.
Proton magnetic resonance spectroscopy metabolite ratios were determined for NAA/Cr,
Cho/Cr, and mI/Cr. Ratios were quantified automatically with vendor-supplied software.
In 1H-MRS, the measured Cr peak includes both the metabolites Cr and phosphocreatine
and is thought to be a reliable marker of brain energy metabolism, often used as a relatively
stable reference level. The measured NAA peak includes NAA and N-
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acetylaspartylglutamate. N-acetylaspartate is an amino acid thought to reflect general
neuronal integrity/viability (17) and may also reflect brain mitochondrial function (18). The
mI metabolite is located in glial cells and is a physiologically important osmolyte in the
brain (19). It is generally considered to be a marker of microglial and astrocyte activation,
suggesting that increased mI could be an indicator of neuroinflammation. Among the
pathways involved in neurodegeneration in AD, neuroinflammation has been consistently
identified (20). The measured Cho is a sum of phosphorylcholine,
glycerophosphorylcholine, and a small percentage of free choline. Hence, Cho is considered
to be a cell membrane marker. There is also evidence (21) that Cho may generally reflect not
only membrane turnover generally, but in the context of Alzheimer's disease, Cho may also
specifically reflect membrane turnover in cholinergic (acetylcholine) neurons. Acetylcholine
neurons may not only have greater amounts of Cho than noncholinergic neurons, but may
also be selectively vulnerable to early AD pathology.
Cognitive Assessment
The Mini-Mental State Examination (22) was used as a screening inclusion criterion and as
a measure of general cognitive/ intellectual performance for further analyses. Memory was
assessed through a verbal list learning test (Rey Auditory Verbal Learning Test) (23).
Attention/executive function was assessed through the accuracy performance on a visual-
spatial version of the 1-back task (24) and Trail Making Test part B (25). Semantic fluency
was measured through the animal naming version test. Finally, speed of processing was
measured by the Digit-Symbol Coding Test. These measures were combined into a single
global cognitive score. Factor analyses techniques have demonstrated the feasibility and
reliability of the use of a g or composite factor as representative of cognitive architecture
(26,27).
Statistical Analyses
General linear models (GLM) were fitted to estimate the effect of APOE status (E3/E3
homozygotes vs. E4 carriers), age (as a continuous variable), and the interaction of APOE ×
age on the 1H-MRS metabolite ratios. Gender was also considered in the models.
Next, we sought to fit a structural equation model for the causal relationships between
APOE polymorphism, age, and the interaction between them on cognitive performance, with
both direct effects on cognition, and indirect effects through brain metabolites measured
by 1H-MRS. Structural equation modeling is a statistical method that can estimate the causal
effect of paths between one or more exogenous variables (independent variables) and one or
more endogenous variables (dependent variables), directly, or mediated by other variables
(28). In our modeling, APOE genotype, age, and the interaction between them were
considered as exogenous variables. A latent general cognitive ability factor was created from
the loadings of the specific individual neuropsychological tests; this factor was considered
as an endogenous variable in the model. Additionally, a latent 1H-MRS factor was created
from the loadings of individual brain metabolite ratios; this factor was considered as
mediator between the effect of APOE, age, and APOE × age interaction on the cognitive
factor. To validate the proposed model, we first fitted a model without preliminary
assumptions about the relative causal effects of paths among the endogenous, exogenous,
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and mediating variables. To obtain a more parsimonious model, progressive steps were
taken to remove nonsignificant paths from the initial model that additionally improved the
overall goodness of fit. For that purpose, the Wald test was used to identify paths that might
be dropped, improving the model chi-square overall fit. The chi-square/degrees of freedom
ratio, the Bentler's comparative fit index (CFI), and the root mean square error of
approximation (RMSEA) were used to assess overall goodness of fit of the covariance
structure of the models. Models were fitted using a maximum likelihood parameter
estimation method.
All the statistical analyses were performed with SAS software version 9.3 (SAS Institute
Inc., Cary, North Carolina) using GLM and CALIS procedures.
Results
Demographic and Cognitive Characteristics
Demographic characteristics and cognitive composite scores stratified by APOE status
(carriers of the APOE E4 allele vs. E3 homozygotes) and age as based on a median split of
the sample (<65 years vs. ≥65 years) are provided in Table 1 (age was split for presentation
purposes in this table). Age range was 50 to 64 years (SD = 4.66) for the subjects younger
than 65 years and 65 to 86 years (SD = 5.90) for the subjects older than 65 years. Gender
distribution showed an imbalance in the APOE E4 subgroup. There was no influence of
APOE genotype or age on years of education. Regarding cognition, an effect of age was
detected; as expected, older subjects performed worse than younger subjects, and older
APOE E4 carriers showed the worst neurocognitive performance. No influence of APOE or
the interaction between APOE and age on cognition was found. Gender did not show an
effect on cognition.
1H-MRS Metabolite Ratios
Proton magnetic resonance spectroscopy metabolite ratios to Cr in relation to age and
stratified by APOE genotype are plotted in Figure 1. As is apparent, older E4 carriers had
higher Cho/Cr and mI/Cr ratios. Individual GLM analysis examining the effect of APOE
polymorphism, age (as a continuous variable), and APOE × age interaction on the 1H-MRS
metabolite ratios are detailed in the Figure 1 legend. The ES for the comparison between
older carriers of APOE E4 and younger APOE E3 homozygotes was medium (.66) for mI
and medium (approaching large) .76 for Cho (age was dichotomized after median split for
calculation of ES) (Figure 2). Given the imbalance in gender, we also conducted the above
analyses adjusting by gender. Gender did not show an interaction with APOE or age and
hence was not considered further.
Structural Equation Modeling
To estimate the model, two latent factors were created: a 1H-MRS metabolites factor and a
cognitive factor. Choline/Cr and mI/Cr were included in the 1H-MRS factor, as they showed
an effect on the previous GLM analysis (effect of APOE and APOE × age on Cho/Cr; effect
of age and APOE × age on mI/Cr). The cognitive latent factor was comprised of the
individual cognitive test scores.
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An initial general model, without any prior assumptions about the relations between
exogenous variables (APOE, age, and their interaction), including direct effects on both the
latent 1H-MRS factor and the latent general cognition factor, as well as mediator effects on
cognition through 1H-MRS metabolites, fit the data well, as indicated by goodness of fit
statistics (chi-square = 43.28/df = 35/p = .16; CFI = .99; RMSEA = .05). Specifically, this
model included direct effects of APOE, age, and APOE × age on cognition and indirect
effects of the same variables through 1H-MRS metabolites. However, inspection of the
individual paths of this general model showed that multiple and critical path weights were
not significant.
Therefore, we next attempted to establish that by progressively deleting statistically
nonsignificant paths, we would improve global goodness of fit and increase path weights
and model parsimony. In this iterative process, with respect to cognition, we found no
significant direct effect of APOE × age interaction. With respect to the 1H-MRS factor, we
found no significant effect of age independent from the effect of APOE..
In the resultant more parsimonious final model (chi-square = 44.25/df = 38/p = .22; CFI = .
99; RMSEA = .04), the interaction between APOE and age had a significant effect on
the 1H-MRS factor as shown in Figure 3. Additionally, the path from the 1H-MRS factor
(including Cho/Cr and mI/Cr) to the cognitive factor demonstrated a significant effect (p < .
01). This indicated that the 1H-MRS metabolites were in a mediating relationship between
the APOE × age interaction variable and the cognition factor. The direction of the paths
were as expected, older APOE E4 carriers had higher 1H-MRS metabolite ratios (Cho/Cr
and mI/Cr), and higher 1H-MRS ratios of these metabolites correlated with lower cognitive
performance. As expected, age also had a highly significant and negative effect on
cognition. APOE genotype also showed a direct effect on 1H-MRS and an indirect effect on
cognition. The final model with the standardized path coefficients is shown in Figure 3. The
successive steps taken to obtain the final model are summarized in Table S3 in Supplement
1.
Discussion
This is the first study to find significant APOE genotype effects on 1H-MRS metabolites in a
healthy aging population. Specifically, GLM analyses indicated that Cho/Cr and mI/Cr
ratios were influenced by an APOE × age interaction (such that older APOE E4 carriers had
higher ratios than other subgroups). In addition, Cho/ Cr ratio was independently modulated
by a main effect of APOE (E4 carriers had higher ratios than E3/E3 homozygotes), and
mI/Cr ratio was independently modulated by a main effect of age (older subjects had higher
ratios than younger subjects).
Structural equation modeling was used to integrate causal relationships between APOE, age,
and the interaction between APOE and age on cognition through 1H-MRS metabolites. In
the final optimized structural equation model cognition was modulated by APOE indirectly
through an intermediary neurochemical measure (including both Cho/Cr and mI/Cr).
Interestingly, no direct paths from APOE to cognition were present, in keeping with notions
of intermediate phenotype (29) and the logic of our model. Effects of the interaction
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between APOE and age, as well as the effect of APOE alone on 1H-MRS were also
significant. Brain metabolite ratios Cho/Cr and mI/Cr were thus sensitive to a variety of
inputs in our sample (older subjects and carriers of the APOE E4 allele). As expected, our
results also suggest that older age had a detrimental effect on cognition.
Our structural equation model had several salient features. First and foremost, it
demonstrated a strong and significant path relationship between the interaction variable of
APOE × age and the composite 1H-MRS metabolite variable. This was in keeping with our
overarching conceptual notion that genotypic effects would become larger with age as
compensatory systems attenuate. Second, the model demonstrated a significant path (p < .
01) from the 1H-MRS variable to cognition, in the predicted neurobiologically plausible
direction (higher Cho and mI predicted lower cognition). No direct effect of APOE on
cognition was found, suggesting that 1H-MRS was an important mediating variable. Last,
we found an effect of age on cognition but not on 1H-MRS metabolites, in keeping with the
literature (see below). We note that our model was not fully overlapping with our GLM
results. This was due to several factors. Our model was, in part, driven by parsimony to most
clearly define key aspects of our data structure. Moreover, the structural equation model's
path weights were based on multiple covariance structures, mediating variables, a 1H-MRS
latent variable that included both Cho/Cr and mI/Cr ratios, and a latent cognitive variable,
considered simultaneously in an interactive causal assumption modeling. Resultant path
weights were dependent on all other paths and structured by the logic of the designated
model to maximize goodness of fit. The GLM approach, instead, took into account effects of
independent variables on individual brain metabolite ratios.
Interactive associations between aging and APOE status on 1H-MRS metabolites and
cognition have not been previously reported. Generally, increases in Cho/Cr found in older
APOE E4 carriers suggest greater membrane turnover or cycling, in accord with degradation
and demands for repair (30,31). Little is known about APOE interactions with cholinergic
neurons, another possible source of Cho. Speculatively, because APOE E4 is associated with
earlier age of AD onset (32), it may consequently compromise cholinergic neurons known to
be vulnerable to early AD pathology.
It has been previously suggested (2,30) that the initial 1H-MRS change in the pathologic
progression of AD is an increase in mI/Cr ratio. Myo-inositol is a marker predominantly
present in astrocytes that may reflect glial proliferation or inflammatory activity. More
specifically, microglial activation as an indicator of neuroinflammation has been considered
an early event in the pathogenesis of AD, as demonstrated by the positron emission
tomography ligand [11C](R)-PK11195, specific for binding activated microglia (33).
Likewise, it has been suggested that APOE E4 may confer some of its risk for AD by
modulating immune responses (34,35). In keeping with this line of evidence, a recent review
has suggested that chronic inflammation may cause dysregulation of mechanisms to clear
damaged and misfolded proteins (mislocalization and hyperphosphorylation of tau) that
accumulate with age (36), a process that could start years before AD symptoms first
manifest.
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Several other points about our study may be worth considering. One potential concern in the
quantification of 1H-MRS metabolites is that age-dependent atrophy of the precuneus/
posterior cingulate voxel might affect the measurements. We did not expect atrophic
changes to be large, as our sample was comprised of cognitively healthy individuals who did
not meet criteria for MCI or dementia. Furthermore, in principle, the metabolite ratios
should not be affected by the total signal decrease due to reduced tissue and increment of
cerebrospinal fluid in the voxel as a consequence of normal brain aging. Nevertheless, we
also performed a cortical thickness analysis of the posterior cingulate/precuneus area using
Freesurfer software (Martinos Center for Biomedical Imaging, Boston, Massachusetts), and
found no effect of APOE, age, or APOE × age interaction.
Age effects on 1H-MRS metabolites have been inconsistently described, have been small,
and have been dependent on metabolite and voxel placement [see Haga et al. (37) for a
systematic review]. In keeping with this view, we found that age had inconsistent effects
on 1H-MRS metabolites in an analysis-dependent manner. In our sample, NAA/Cr ratios
were found not to be influenced by APOE, age, or their interaction. This result may be
viewed as counterintuitive, as NAA is considered a marker of neuronal viability that is likely
to be affected in normal brain aging. Nevertheless, NAA levels have been found to be
relatively stable in cognitively normal older adults during longitudinal studies in different
cohorts (4,38). Additionally, our negative findings of the influence of NAA on aging and
cognition are in line with those of a very recent study (39) that concluded that whole-brain
NAA concentrations are conserved throughout normal aging and are not associated with
cognition.
Ratios of 1H-MRS metabolites to creatine are commonly reported in the literature because
brain creatine is relatively stable over the course of months within an individual (40), and
unaffected by most neurological diseases (31), making the Cr peak suitable as an internal
reference. We used proton brain exam (PROBE) as an automated metabolite quantification
method, which provides ratio-based (to Cr) quantifications. Quantifying metabolite
intensities by referencing to an internal standard is preferred in clinical 1H-MRS (30).
Proton brain exam is considered a well-suited method for the analysis of large datasets in
that it allows direct comparison of our results with the majority of previous studies in the
field (38). However, it is important to note that the proton brain exam metabolite
quantification method has the limitation of not providing specific goodness-of-fit measures
of the spectral data. In addition, we acknowledge that increased creatine levels with age
have also been reported (41). In our study, increased creatine levels would have caused
decreased ratios of mI and Cho (by having a greater denominator), which are the opposite of
our findings (mI and Cho increased with age).
As a cross-sectional study, our results may have been subject to sample acquisition biases.
Particularly, we cannot rule out the possibility that there might have been a survivor effect
related to APOE status, since life expectancy in APOE E4 carriers is reduced due to
associated increased risk of cardiovascular disease and Alzheimer's disease. In effect, we
might have been assaying a relatively healthy, surviving older E4 population. Importantly,
this would work against our main hypothesis, i.e., this subsample would be less likely to
demonstrate magnetic resonance spectroscopy abnormalities, and thus our results would
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appear to be robust. Nevertheless, we acknowledge that as a cross-sectional study,
inferences are limited and may be affected by sample ascertainment biases.
Finally, it is important to note that this is not intended to be a clinical biomarker study, as we
were not utilizing 1H-MRS measures to characterize MCI, predict AD, or track progression
of AD. Rather, we sought to understand how the APOE E4 variant might adversely impact
the neurobiology of the aging brain.
In summary, we found that APOE genotype and its interaction with age directly and
significantly, modulated brain metabolites (Cho/Cr and mI/Cr). Both Cho/Cr and mI/Cr
ratios were increased in older APOE E4 carriers, suggesting increased membrane turnover
and inflammatory changes. Furthermore, these 1H-MRS ratios impacted a composite
measure of cognition in our structural equation model. Thus, brain metabolites appeared to
have a role in mediating the relationship between APOE and cognition. Finally, we suggest
that this set of findings provides a window on brain changes in the posterior precuneus/
cingulate region, associated with APOE E4, that may precede the development of clinically
significant impairments in cognition and everyday function.
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Figure 1.
Proton magnetic resonance spectroscopy metabolite ratios of the subjects and their relation
to APOE genotype and age. Scatter plots display proton magnetic resonance spectroscopy
metabolite ratios for APOE E3/E3 homozygotes and APOE E4 carriers. Choline (Cho)/
creatine (Cr) and myoinositol (mI)/Cr are significantly elevated in older APOE E4 carriers
(A, B). N-acetylaspartate (NAA)/Cr is similar across groups (C). For Cho/Cr, general linear
model analysis shows an overall model fit near significance (F3,106 = 2.41, p = .07; R2 = .
06), with APOE genotype having a significant modulatory effect (F1,108 = 4.55, p = .03), as
does APOE × age interaction term (F1,108 = 5.23, p = .02); age effect is not significant
(F1,108 = 1.48, p = .23). Myo-inositol/Cr ratios show a significant overall model (F3,106 =
2.72, p = .05; R2 = .07), with an independent effect of age (F1,108 = 3.85, p = .05) and a near
significant effect of the APOE × age interaction (F1,108 = 3.63, p = .06); APOE is not
significant in the model (F1,108 = 2.55, p = .11). For NAA/Cr ratios (overall model fit F3,106
= .24, p = .86, R2 = .01), no effects of APOE (F1,108 = .69, p = .41), age (F1,108 = .45, p = .
51), or the interaction between APOE and age (F1,108 = .72, p = .40) are found.
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Figure 2.
Effect sizes (ES) for the comparison between older E4 carriers and younger E3 homozygotes
on proton magnetic resonance spectroscopy (1H-MRS) metabolite ratios. Bars represent ES
for the difference between older E4 carriers and younger E3 homozygotes on choline (Cho)/
creatine (Cr) (ES = .76), myo-inositol (mI)/Cr (ES = .66), and N-acetylaspartate (NAA)/Cr
(ES = .06).
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Figure 3.
Final structural equation model with standardized coefficients. Figure shows the direct effect
of the interaction between APOE and age and APOE alone on the proton magnetic
resonance spectroscopy factor (comprising choline [Cho]/creatine [Cr] and myo-inositol
[mI]/Cr), the mediator effect of the interaction between APOE and age on cognition through
proton magnetic resonance spectroscopy metabolites, and the direct negative effect of age on
cognition. Older APOE E4 carriers have higher Cho/Cr and mI/Cr levels, and higher Cho/Cr
and mI/Cr levels are associated with worse cognitive performance. Path weights and their
significance are shown in this figure. Goodness-of-fit indexes are described in the text.
MMSE, Mini-Mental State Examination; 1H-MRS, proton magnetic resonance
spectroscopy; TMT-B, Trail Making Test part B.
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